ArticleFrontiers in neuroscience2025
Superoxide dismutase is associated with cerebral small vessel disease burden and vascular mild cognitive impairment in elderly patients.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine the associations between superoxide dismutase (SOD) levels and the burden of cerebral small vessel disease (CSVD), as well as vascular mild cognitive impairment (VaMCI), in elderly patients. Methods: In this study, a cohort of 286 elderly individuals was included. Each participant received a comprehensive cognitive assessment. Plasma SOD levels were evaluated. The cumulative CSVD burden was quantified using an ordinal scale ranging from 0 to 4, based on four key imaging indicators of CSVD: white matter hyperintensity, deep cerebral microbleeds, lacunes, and enlarged perivascular spaces in the basal ganglia. To evaluate the associations among SOD levels, CSVD burden, and cognitive function, we employed binary logistic regression analysis, tests for trend, receiver operating characteristic curve analysis, and mediation analysis. Results: After adjusting for potential confounders, multivariate logistic regression analysis revealed that elevated levels of SOD were significantly associated with a reduced risk of VaMCI (OR: 0.919; 95% CI: 0.896-0.943; Conclusion: Elevated SOD levels serve as a protective factor against severe CSVD burden and VaMCI in elderly patients. A portion of the protective effect of increased SOD on VaMCI may be attributed to its role in mitigating the severity of CSVD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.